Unmet needs in the first-line treatment of follicular lymphoma.

about

Unmet needs in the first-line treatment of follicular lymphoma.

Item

http://www.wikidata.org/entity/Q50710717

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Unmet needs in the first-line treatment of follicular lymphoma.

@en

Unmet needs in the first-line treatment of follicular lymphoma.

@nl

type

Item

label

Unmet needs in the first-line treatment of follicular lymphoma.

@en

Unmet needs in the first-line treatment of follicular lymphoma.

@nl

prefLabel

Unmet needs in the first-line treatment of follicular lymphoma.

@en

Unmet needs in the first-line treatment of follicular lymphoma.

@nl

P1476

Unmet needs in the first-line treatment of follicular lymphoma.

@en

P2093

C Casulo

http://www.w3.org/2001/XMLSchema#string

C R Flowers

http://www.w3.org/2001/XMLSchema#string

J W Friedberg

http://www.w3.org/2001/XMLSchema#string

L Nastoupil

http://www.w3.org/2001/XMLSchema#string

N H Fowler

http://www.w3.org/2001/XMLSchema#string

P2860

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Detecting an overall survival benefit that is derived from progression-free survival

P304

2094-2106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDX189

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28430865

http://www.w3.org/2001/XMLSchema#string

P932

5834060

http://www.w3.org/2001/XMLSchema#string